[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-417309-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-417309-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","barriers-to-adherence-with-corticosteroid-eye-drops-in-patients-with-uveitis","Barriers to Adherence with Corticosteroid Eye Drops in Patients with Uveitis","","Assess patient barriers to adherence with corticosteroid eye drops among ocular inflammatory disorder patients across the United States. Conducted a multicenter survey study of adults and pediatric patients with uveitis at multiple ophthalmology sites. Collected self-reported adherence patterns and reasons for nonadherence. Results highlighted most patients taking drops as directed, yet substantial practical obstacles persisted: dosing frequency, complex regimens, administration difficulty, and early depletion of medication, while cost barriers were rarely reported.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/barriers-to-adherence-with-corticosteroid-eye-drops-in-patients-with-uveitis/417309/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/barriers-to-adherence-with-corticosteroid-eye-drops-in-patients-with-uveitis/417309.png","ImageObject",300,407,{"name":42,"@type":43},"anakgang17","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study purpose regarding corticosteroid eye drops in uveitis patients?","Question",{"text":63,"@type":64},"To assess patient-reported barriers to adherence with corticosteroid eye drops in patients with ocular inflammatory disorders across the United States.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were barriers to adherence measured in the study?",{"text":68,"@type":64},"Eligible patients completed a self-report survey to evaluate barriers to adherence with corticosteroid eye drops.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main reasons patients reported for nonadherence?",{"text":72,"@type":64},"Key reported barriers included medication frequency limits, polypharmacy, difficulty administering drops, missing refills, and occasionally running out of medication early.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},417309,1790695771,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","| Original Article |\n| --- |\n|  |\n\nBarriers to Adherence with Corticosteroid Eye Drops in Patients  \nwith Uveitis  \nKaren Sun1, Rayna Marshall2, Michael Frankland3, Amal Taylor4, Cynthia Montana4, Eric Crowell3, Karen R. Armbrust5,6, Laura Kopplin7, Meghan Berkenstock8  \n1Georgetown School of Medicine, Washington, DC, USA, 2Drexel University College of Medicine, Philadelphia, PA, USA, 3Department of Ophthalmology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA, 4Department of Ophthalmology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA, 5Department of Ophthalmology, University of Minnesota, Minneapolis, MN, USA, 6Department of Ophthalmology, Minneapolis Veterans Affairs Health Care System, Minneapolis, MN, USA, 7Department of Ophthalmology, University of Wisconsin Madison School of Medicine and Public Health, Madison, WI, USA, 8Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA  \nAbstract  \nPurpose: To assess the patient barriers to adherence with corticosteroid eye drops in patients with ocular inflammatory disorders across the United States.  \nMethods: This was a multicenter study of adult and pediatric patients with uveitis undergoing treatment with corticosteroid eye drops. Sites included the Johns Hopkins Wilmer Eye, the University of Texas at Austin, the University of Wisconsin-Madison, the University of Minnesota, the Minneapolis Veterans Administration Hospital, and the Washington University of St. Louis. Eligible patients completed a self-reporting survey to assess barriers to adherence with corticosteroid eye drops.  \nResults: The survey was completed fully by 94 subjects and partially by 20 (115 in total), of whom were 66% White, 60% female, and 47% had a college or advanced degree. While some patients (5.5%, n = 6) self-reported never taking their corticosteroid eye drops as prescribed, most reported taking the drops as directed (54.1%, n = 59) or at least 90% of the time (29.4%, n = 32). Reasons for nonadherence were explored: 56% of patients used a corticosteroid eye drop more than once a day, and 13% found frequency a limitation to adherence. Many patients had polypharmacy, 43% took 4 or more medications, and 50% took 1 or more drops in addition to a corticosteroid eye drop. Patients also reported difficulty reading the writing on drop bottles (39%) and poor vision limiting application into the eye (17%). Almost a quarter (24%) of patients occasionally ran out of their drop before the next refill. Most patients did not report cost (98%) or insurance loss (97%) as a barrier to obtaining a refill.  \nConclusions: Barriers to corticosteroid eye drop treatments for ocular inflammatory disease include difficulty with medication frequency, polypharmacy, medication administration, missing refills, and running out of medication early. Addressing these barriers may improve adherence with corticosteroid eye drops to achieve treatment goals.  \nKeywords: Adherence, Barriers, Corticosteroids, Ocular inflammation, Uveitis  \nAddress for correspondence: Meghan Berkenstock, 600 N. Wolfe Street, Maumenee Building, Third Floor, Baltimore, MD 21087, USA.  \nE‑[mail: mberken2@jhmi.edu](mail: mberken2@jhmi.edu)  \nSubmitted: 05‑Nov‑2024; Revised: 09‑Jun‑2025; Accepted: 26‑Aug‑2025; Published: 19‑Dec‑2025  \nIntroductIon  \nUveitis is the fifth most common cause of preventable blindness in the United States.1 Based on the Multicenter Uveitis Steroid Treatment Trial, the yearly direct healthcare cost, both medical and pharmaceutical, of patients with noninfectious uveitis was estimated to range from $13,728 to $32,268 in 2009,  \n\n| Access this article online |  |\n| --- | --- |\n| Quick Response Code:\u003Cbr>| Website:\u003Cbr>[https://journals.lww.com/joco](https://journals.lww.com/joco) |\n|  | DOI:\u003Cbr>10.4103/joco.joco_239_24 |\n\ndepending on whether treatment included corticosteroid eye drops alone or required use of immunosuppressive agents.2 Without t","cbCaie28UzuubcJ7","https://ap.wps.com/l/cbCaie28UzuubcJ7","pdf",1884004,11,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the study purpose regarding corticosteroid eye drops in uveitis patients?\",\"answer\":\"To assess patient-reported barriers to adherence with corticosteroid eye drops in patients with ocular inflammatory disorders across the United States.\"},{\"question\":\"How were barriers to adherence measured in the study?\",\"answer\":\"Eligible patients completed a self-report survey to evaluate barriers to adherence with corticosteroid eye drops.\"},{\"question\":\"What were the main reasons patients reported for nonadherence?\",\"answer\":\"Key reported barriers included medication frequency limits, polypharmacy, difficulty administering drops, missing refills, and occasionally running out of medication early.\"}]","Barriers to Adherence with Corticosteroid Eye Drops in Patients with Uveitis | PDF",1790608807,28]